These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18769609)

  • 1. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.
    Neyns B; Meert V; Vandenbroucke F
    Curr Oncol; 2008 Aug; 15(4):196-7. PubMed ID: 18769609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.
    Okamoto K; Maeda H; Shiga T; Shiga M; Dabanaka K; Hanazaki K; Kobayashi M
    World J Gastroenterol; 2015 Mar; 21(12):3746-9. PubMed ID: 25834345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of psoriasis pustolosa palmaris induced by cetuximab.
    Marinello E; Pastorelli D; Alaibac M
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26994052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
    Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review.
    Fornasier G; Francescon S; Baldo P
    Adv Ther; 2018 Oct; 35(10):1497-1509. PubMed ID: 30218345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
    Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
    Kubo A; Hashimoto H; Takahashi N; Yamada Y
    World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
    Pantelic A; Markovic M; Pavlovic M; Jancic S
    J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
    Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
    Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.
    De Tursi M; Zilli M; Carella C; Auriemma M; Lisco MN; Di Nicola M; Di Martino G; Natoli C; Amerio P
    Onco Targets Ther; 2017; 10():3007-3015. PubMed ID: 28670133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
    Garibaldi DC; Adler RA
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.
    Segal NH; Gada P; Senzer N; Gargano MA; Patchen ML; Saltz LB
    Clin Colorectal Cancer; 2016 Sep; 15(3):222-7. PubMed ID: 26975418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
    Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
    J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.